MARS Bioimaging is a Christchurch, New Zealand–based medical device company specializing in spectral molecular imaging. Leveraging Medipix technology originally developed at CERN by the Medipix3 Collaboration, the company has created a commercially available portable spectral photon-counting CT scanner. The compact system can simultaneously visualise soft tissue, bone, blood vessels and metallic implants without the need for injected contrast agents. Target use cases span orthopaedics, cardiovascular imaging and the development of next-generation contrast agents for research. With fresh capital, the team plans to accelerate commercial adoption in the United States, New Zealand and emerging markets such as India. The company is led by CEO Dr. Ojas Mahapatra and supported by chairman Chris Stoelhorst. No revenue, user or other operating metrics were disclosed in the article.

Total raised

$15M

Funding rounds

1

Latest round

Series A

Latest activity

Jan 2026